Selected research
Industry Research
Viral Vector CTDMO Services Industry Research Report 2026
Market perspective
The global Viral Vector CTDMO Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Viral Vector CTDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Viral Vector CTDMO Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Viral Vector CTDMO Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Viral Vector CTDMO Services include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Batavia Biosciences, HALIX, Catalent Biologics and Oxford BioMedica and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Viral Vector CTDMO Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Viral Vector CTDMO Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Viral Vector CTDMO Services Market by Company
AGC Biologics
Lonza
Charles River Laboratories
Thermo Fisher Scientific
SK pharmteco
Batavia Biosciences
HALIX
Catalent Biologics
Oxford BioMedica
Biovian
Viral Vector CTDMO Services Segment by Type
Adeno-associated Viral
Adenoviral
Lentiviral
Retroviral
Viral Vector CTDMO Services Segment by Application
Gene Therapy
Cell Therapy
Vaccine Development
Viral Vector CTDMO Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector CTDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vector CTDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector CTDMO Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vector CTDMO Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Adeno-associated Viral
- Adenoviral
- Lentiviral
- Retroviral
Applications
- Gene Therapy
- Cell Therapy
- Vaccine Development
Companies covered
- AGC Biologics
- Lonza
- Charles River Laboratories
- Thermo Fisher Scientific
- SK pharmteco
- Batavia Biosciences
- HALIX
- Catalent Biologics
- Oxford BioMedica
- Biovian
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Viral Vector CTDMO Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Adeno-associated Viral
- 2.2.3 Adenoviral
- 2.2.4 Lentiviral
- 2.2.5 Retroviral
- 2.3 Viral Vector CTDMO Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Gene Therapy
- 2.3.3 Cell Therapy
- 2.3.4 Vaccine Development
- 2.4 Assumptions and Limitations
3 Viral Vector CTDMO Services Breakdown Data by Type
- 3.1 Global Viral Vector CTDMO Services Historic Market Size by Type (2021-2026)
- 3.2 Global Viral Vector CTDMO Services Forecasted Market Size by Type (2027-2032)
4 Viral Vector CTDMO Services Breakdown Data by Application
- 4.1 Global Viral Vector CTDMO Services Historic Market Size by Application (2021-2026)
- 4.2 Global Viral Vector CTDMO Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Viral Vector CTDMO Services Market Perspective (2021-2032)
- 5.2 Global Viral Vector CTDMO Services Growth Trends by Region
- 5.2.1 Global Viral Vector CTDMO Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Viral Vector CTDMO Services Historic Market Size by Region (2021-2026)
- 5.2.3 Viral Vector CTDMO Services Forecasted Market Size by Region (2027-2032)
- 5.3 Viral Vector CTDMO Services Market Dynamics
- 5.3.1 Viral Vector CTDMO Services Industry Trends
- 5.3.2 Viral Vector CTDMO Services Market Drivers
- 5.3.3 Viral Vector CTDMO Services Market Challenges
- 5.3.4 Viral Vector CTDMO Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Viral Vector CTDMO Services Players by Revenue
- 6.1.1 Global Top Viral Vector CTDMO Services Players by Revenue (2021-2026)
- 6.1.2 Global Viral Vector CTDMO Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Viral Vector CTDMO Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Viral Vector CTDMO Services Head Office and Area Served
- 6.4 Global Viral Vector CTDMO Services Players, Product Type & Application
- 6.5 Global Viral Vector CTDMO Services Manufacturers Established Date
- 6.6 Global Viral Vector CTDMO Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Viral Vector CTDMO Services Market Size (2021-2032)
- 7.2 North America Viral Vector CTDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Viral Vector CTDMO Services Market Size by Country (2021-2026)
- 7.4 North America Viral Vector CTDMO Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Viral Vector CTDMO Services Market Size (2021-2032)
- 8.2 Europe Viral Vector CTDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Viral Vector CTDMO Services Market Size by Country (2021-2026)
- 8.4 Europe Viral Vector CTDMO Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Viral Vector CTDMO Services Market Size (2021-2032)
- 9.2 Asia-Pacific Viral Vector CTDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Viral Vector CTDMO Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Viral Vector CTDMO Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Viral Vector CTDMO Services Market Size (2021-2032)
- 10.2 South America Viral Vector CTDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Viral Vector CTDMO Services Market Size by Country (2021-2026)
- 10.4 South America Viral Vector CTDMO Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Viral Vector CTDMO Services Market Size (2021-2032)
- 11.2 Middle East & Africa Viral Vector CTDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Viral Vector CTDMO Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Viral Vector CTDMO Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AGC Biologics
- 12.1.1 AGC Biologics Company Information
- 12.1.2 AGC Biologics Business Overview
- 12.1.3 AGC Biologics Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.1.4 AGC Biologics Viral Vector CTDMO Services Product Portfolio
- 12.1.5 AGC Biologics Recent Developments
- 12.2 Lonza
- 12.2.1 Lonza Company Information
- 12.2.2 Lonza Business Overview
- 12.2.3 Lonza Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.2.4 Lonza Viral Vector CTDMO Services Product Portfolio
- 12.2.5 Lonza Recent Developments
- 12.3 Charles River Laboratories
- 12.3.1 Charles River Laboratories Company Information
- 12.3.2 Charles River Laboratories Business Overview
- 12.3.3 Charles River Laboratories Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.3.4 Charles River Laboratories Viral Vector CTDMO Services Product Portfolio
- 12.3.5 Charles River Laboratories Recent Developments
- 12.4 Thermo Fisher Scientific
- 12.4.1 Thermo Fisher Scientific Company Information
- 12.4.2 Thermo Fisher Scientific Business Overview
- 12.4.3 Thermo Fisher Scientific Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.4.4 Thermo Fisher Scientific Viral Vector CTDMO Services Product Portfolio
- 12.4.5 Thermo Fisher Scientific Recent Developments
- 12.5 SK pharmteco
- 12.5.1 SK pharmteco Company Information
- 12.5.2 SK pharmteco Business Overview
- 12.5.3 SK pharmteco Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.5.4 SK pharmteco Viral Vector CTDMO Services Product Portfolio
- 12.5.5 SK pharmteco Recent Developments
- 12.6 Batavia Biosciences
- 12.6.1 Batavia Biosciences Company Information
- 12.6.2 Batavia Biosciences Business Overview
- 12.6.3 Batavia Biosciences Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.6.4 Batavia Biosciences Viral Vector CTDMO Services Product Portfolio
- 12.6.5 Batavia Biosciences Recent Developments
- 12.7 HALIX
- 12.7.1 HALIX Company Information
- 12.7.2 HALIX Business Overview
- 12.7.3 HALIX Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.7.4 HALIX Viral Vector CTDMO Services Product Portfolio
- 12.7.5 HALIX Recent Developments
- 12.8 Catalent Biologics
- 12.8.1 Catalent Biologics Company Information
- 12.8.2 Catalent Biologics Business Overview
- 12.8.3 Catalent Biologics Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.8.4 Catalent Biologics Viral Vector CTDMO Services Product Portfolio
- 12.8.5 Catalent Biologics Recent Developments
- 12.9 Oxford BioMedica
- 12.9.1 Oxford BioMedica Company Information
- 12.9.2 Oxford BioMedica Business Overview
- 12.9.3 Oxford BioMedica Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.9.4 Oxford BioMedica Viral Vector CTDMO Services Product Portfolio
- 12.9.5 Oxford BioMedica Recent Developments
- 12.10 Biovian
- 12.10.1 Biovian Company Information
- 12.10.2 Biovian Business Overview
- 12.10.3 Biovian Revenue in Viral Vector CTDMO Services Business (2021-2026)
- 12.10.4 Biovian Viral Vector CTDMO Services Product Portfolio
- 12.10.5 Biovian Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst